North American Report

Asthma Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

 Breaking News
  • No posts were found

Asthma Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

February 15
18:56 2023
Asthma Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments
Las Vega (Nevada), United States //— As per DelveInsight’s assessment, globally, Asthma pipeline constitutes 100+ key companies continuously working towards developing 100+ Asthma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Asthma Overview

Asthma is a chronic disease that affects the airways. It is characterized by inflammation and spasm of the airways. The airways are tubes that carry air in and out of the lungs. If a person has asthma, the inside walls of the airways become sore and swollen. The air passages in the lungs become narrow due to inflammation and tightening of the muscles around the small airways. This causes asthma symptoms: cough, wheeze, shortness of breath, and chest tightness

 

Asthma Pipeline Insight, 2023 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Asthma Market.

 

The Asthma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Asthma Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Asthma treatment therapies with a considerable amount of success over the years. Asthma Key players such as – Tarus therapeutics, Lanier Biotherapeutics, Landos Biopharma, KeyMed Biosciences, HoffmanLa-Roche, Kinaset therapeutics, Chia Tai Tianqing Pharmaceutical Group, Sterna Biologics, Aldeyra Therapeutics, GlaxoSmithKline, AstraZeneca, Avillion LLP, and others, are developing therapies for the Asthma treatment 
  • Asthma Emerging therapies such as – A2BR inhibitors, LNR 125.38, LABP-73, CM326, RG6314, KN-002, TQC2731, SB010, ADX-629, GSK3511294, BGF MDI, PT027, and others are expected to have a significant impact on the Asthma market in the coming years.   
  • In May 2022, Avillion LLP, announced that the US Food and Drug Administration (FDA) has accepted Avillion’s New Drug Application (NDA) for AstraZeneca’s PT027. The proposed indication is for the as-needed treatment or prevention of bronchoconstriction and for the prevention of exacerbations in patients with asthma 4 years of age and older

 

Route of Administration

Asthma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical.
  • Molecule Type

 

Molecule Type

Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

 

Asthma Pipeline Therapeutics Assessment

  • Asthma Assessment by Product Type
  • Asthma By Stage and Product Type
  • Asthma Assessment by Route of Administration
  • Asthma By Stage and Route of Administration
  • Asthma Assessment by Molecule Type
  • Asthma by Stage and Molecule Type

 

DelveInsight’s Asthma Report covers around 100+ products under different phases of clinical development like-

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Some of the key companies in the Asthma Therapeutics Market include:

Key companies developing therapies for Asthma Treatment are – GlaxoSmithKline, AstraZeneca, Novartis, Teva Pharmaceuticals, Sanofi, Boehringer Ingelheim, Merck & Co., Roche, Vectura Group, Cipla Limited, and others

 

Emerging Asthma Drugs Under Different Phases of Clinical Development Include:

  • Research programme: A2BR inhibitors: Tarus therapeutics
  • LNR 125.38: Lanier Biotherapeutics
  • LABP-73: Landos Biopharma
  • CM326: KeyMed Biosciences
  • RG6314: HoffmanLa-Roche
  • KN-002: Kinaset therapeutics
  • TQC2731: Chia Tai Tianqing Pharmaceutical Group
  • SB010: Sterna Biologics
  • ADX-629: Aldeyra Therapeutics
  • GSK3511294: GlaxoSmithKline
  • BGF MDI: AstraZeneca
  • PT027: Avillion LLP

 

Get a Free Sample PDF Report to know more about Asthma Pipeline Therapeutic Assessment – https://www.delveinsight.com/sample-request/asthma-pipeline-insight

 

Asthma Pipeline Analysis:

The Asthma pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Asthma with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Asthma Treatment.
  • Asthma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Asthma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Asthma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Further Asthma product details are provided in the report. Download the Asthma pipeline report to learn more about the emerging Asthma therapies

 

Asthma Pipeline Market Drivers

  • Increasing prevalence of asthma worldwide
  • R&D focus towards developing novel therapies for asthma
  • Increasing healthcare expenditures

 

Asthma Pipeline Market Barriers

  • High cost of asthma medications
  • Inadequate knowledge/Less awareness in under-emerging economies
  • Lack of effective and proven therapies for asthma

 

Scope of Asthma Pipeline Drug Insight    

  • Coverage: Global
  • Key Asthma Companies: Tarus therapeutics, Lanier Biotherapeutics, Landos Biopharma, KeyMed Biosciences, HoffmanLa-Roche, Kinaset therapeutics, Chia Tai Tianqing Pharmaceutical Group, Sterna Biologics, Aldeyra Therapeutics, GlaxoSmithKline, AstraZeneca, Avillion LLP, and others
  • Key Asthma Therapies: A2BR inhibitors, LNR 125.38, LABP-73, CM326, RG6314, KN-002, TQC2731, SB010, ADX-629, GSK3511294, BGF MDI, PT027, and others
  • Asthma Therapeutic Assessment: Asthma current marketed and Asthma emerging therapies
  • Asthma Market Dynamics: Asthma market drivers and Asthma market barriers 

 

Request for Sample PDF Report for Asthma Pipeline Assessment and clinical trials

 

Table of Contents

1

Asthma Report Introduction

2

Asthma Executive Summary

3

Asthma Overview

4

Asthma- Analytical Perspective In-depth Commercial Assessment

5

Asthma Pipeline Therapeutics

6

Asthma Late Stage Products (Phase II/III)

7

Asthma Mid Stage Products (Phase II)

8

Asthma Early Stage Products (Phase I)

9

Asthma Preclinical Stage Products

10

Asthma Therapeutics Assessment

11

Asthma Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Asthma Key Companies

14

Asthma Key Products

15

Asthma Unmet Needs

16 

Asthma Market Drivers and Barriers

17

Asthma Future Perspectives and Conclusion

18

Asthma Analyst Views

19

Appendix

20

About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

 

Download Sample PDF Report to know more about Asthma drugs and therapies

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com